AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21895543 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 224
Study 19675867 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma probe completion thyroidectomy (GPCT)
Number of subjects: 100
Study 19675867 — intervention group
Group type: COMPARATOR
Intervention: Conventional completion thyroidectomy
Number of subjects: 100
Study 17473143 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoprophylaxis plus intermittent pneumatic compression
Number of subjects: 1803
Study 17473143 — intervention group
Group type: COMPARATOR
Intervention: Chemoprophylaxis alone
Number of subjects: 1803
Study 17473143 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoprophylaxis plus intermittent pneumatic compression (more than six hours daily)
Number of subjects: 1803
Study 15148925 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg daily (qd) for 6 weeks
Number of subjects: 64
Study 15148925 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice a day (bid) for 6 weeks
Number of subjects: 64
Study 11939160 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganirelix
Number of subjects: 0
Study 11939160 — intervention group
Group type: COMPARATOR
Intervention: Gonadotrophin-releasing hormone agonists (buserelin, leuprolide, triptorelin)
Number of subjects: 0
Study 9690949 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg orally once daily for 4 days
Number of subjects: 10
Study 7866002 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (points ST36, LI11, RN6, and symptomatic points bilaterally) for 30 minutes daily for 10 days
Number of subjects: 45
Study 7866002 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 45
Study 2562387 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum (15 g/day, divided in three doses with major meals)
Number of subjects: 35
Study 2562387 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 35
Study 1145134 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloxacillin
Number of subjects: 12
Study 1145134 — intervention group
Group type: EXPERIMENTAL
Intervention: Dicloxacillin
Number of subjects: 12
Study 30184309 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory cues
Number of subjects: 181
Study 30184309 — intervention group
Group type: COMPARATOR
Intervention: Unisensory cues
Number of subjects: 181
Study 29158435 — intervention group
Group type: EXPERIMENTAL
Intervention: High diary use
Number of subjects: 393
Study 29158435 — intervention group
Group type: EXPERIMENTAL
Intervention: Very high diary use
Number of subjects: 393
Study 29158435 — intervention group
Group type: COMPARATOR
Intervention: No diary use
Number of subjects: 393
Study 25543065 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption after stress in FHP-HCR (high cortisol responders)
Number of subjects: 58
Study 25543065 — intervention group
Group type: COMPARATOR
Intervention: Placebo intake
Number of subjects: 58
Study 23528148 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management psychosocial intervention
Number of subjects: 48
Study 23528148 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 48
Study 21993043 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-minute rest interval (RI) during horizontal leg press (LP)
Number of subjects: 10
Study 21993043 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-minute rest interval (RI) during horizontal leg press (LP)
Number of subjects: 10
Study 21993043 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-minute rest interval (RI) during chest fly (CF)
Number of subjects: 10
Study 21993043 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-minute rest interval (RI) during chest fly (CF)
Number of subjects: 10
Study 21993043 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-minute and 3-minute rest intervals (RI) during horizontal leg press (LP) and chest fly (CF)
Number of subjects: 10
Study 18060379 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigeminocardiac reflex (TCR) occurrence during surgery
Number of subjects: 40
Study 18060379 — intervention group
Group type: EXPERIMENTAL
Intervention: TCR occurrence during nasal mucosa preparation
Number of subjects: 40
Study 18060379 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein levels after TCR occurrence
Number of subjects: 40
Study 18060379 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of tumor necrosis factor A and noradrenalin levels
Number of subjects: 40
Study 18060379 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine administration
Number of subjects: 40
Study 16469681 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice daily for 14 days
Number of subjects: 222
Study 16469681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 12971705 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional early physiotherapy (AEP) for 45 minutes, five days a week for four weeks starting within the first week since stroke onset
Number of subjects: 156
Study 12971705 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy (RT) group received no professional rehabilitation therapy
Number of subjects: 156
Study 11033383 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-response studies in Phase I
Number of subjects: 0
Study 11033383 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-response studies in Phase II
Number of subjects: 0
Study 11033383 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacodynamic models
Number of subjects: 0
Study 11033383 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-response assessment
Number of subjects: 0
Study 9436670 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (Ig) administered between weeks 5 and 7 of gestation for 2 consecutive days, with a further infusion at week 8.
Number of subjects: 46
Study 9436670 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered between weeks 5 and 7 of gestation for 2 consecutive days, with a further infusion at week 8.
Number of subjects: 46
Study 8292687 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine hydrochloride (2 micrograms/kg)
Number of subjects: 60
Study 8292687 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60
Study 8292687 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with DSM‐III‐R panic disorder
Number of subjects: 60
Study 3538478 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered dose inhaler with conical spacer device
Number of subjects: 0
Study 3538478 — intervention group
Group type: COMPARATOR
Intervention: Metered dose inhaler without conical spacer device
Number of subjects: 0
Study 3538478 — intervention group
Group type: COMPARATOR
Intervention: Nebuliser treatment
Number of subjects: 0
Study 31408652 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior approach POEM
Number of subjects: 150
Study 31408652 — intervention group
Group type: COMPARATOR
Intervention: Posterior approach POEM
Number of subjects: 150
Study 31487231 — intervention group
Group type: EXPERIMENTAL
Intervention: High-tech visual scene displays (VSDs)
Number of subjects: 3
Study 31487231 — intervention group
Group type: COMPARATOR
Intervention: Low-tech isolated picture symbols
Number of subjects: 3
Study 27477525 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 0
Study 27477525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27493757 — intervention group
Group type: EXPERIMENTAL
Intervention: Group medical appointments (GMA's; novel intervention)
Number of subjects: 100
Study 27493757 — intervention group
Group type: COMPARATOR
Intervention: Individual medical appointments (IMA's; care-as-usual; control)
Number of subjects: 100
Study 24213952 — intervention group
Group type: EXPERIMENTAL
Intervention: Late parenteral nutrition (PN) starting on day 8
Number of subjects: 4640
Study 24213952 — intervention group
Group type: COMPARATOR
Intervention: Early parenteral nutrition (PN)
Number of subjects: 4640
Study 22980698 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise program
Number of subjects: 100
Study 22980698 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program
Number of subjects: 100
Study 22980698 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise program
Number of subjects: 100
Study 22980698 — intervention group
Group type: COMPARATOR
Intervention: No exercise program (Control)
Number of subjects: 100
Study 19756527 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram (10 mg)
Number of subjects: 20
Study 17320568 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% mannitol 0.5 g/kg
Number of subjects: 50
Study 17320568 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 2.5 mL/kg
Number of subjects: 50
Study 14634492 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyenylphosphatidylcholine (PPC)
Number of subjects: 789
Study 14634492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 789
Study 14634492 — intervention group
Group type: EXPERIMENTAL
Intervention: PPC
Number of subjects: 789
Study 11007673 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position (Baseline)
Number of subjects: 7
Study 11007673 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position (Diuretic)
Number of subjects: 7
Study 11007673 — intervention group
Group type: COMPARATOR
Intervention: Upright position (Baseline)
Number of subjects: 7
Study 11007673 — intervention group
Group type: COMPARATOR
Intervention: Upright position (Diuretic)
Number of subjects: 7
Study 11007673 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position (Weight change)
Number of subjects: 7
Study 11007673 — intervention group
Group type: COMPARATOR
Intervention: Upright position (Weight change)
Number of subjects: 7
Study 8832319 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma nail
Number of subjects: 1794
Study 8832319 — intervention group
Group type: COMPARATOR
Intervention: DHS nail
Number of subjects: 1794
Study 1471489 — intervention group
Group type: EXPERIMENTAL
Intervention: Fornix-based flap procedure
Number of subjects: 18
Study 1471489 — intervention group
Group type: COMPARATOR
Intervention: Limbus-based flap procedure
Number of subjects: 18
Study 6378422 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 138
Study 6378422 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (nitrates and beta-blockers)
Number of subjects: 138
Study 3511709 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (333 mg three times daily by mouth for 7 days)
Number of subjects: 58
Study 3511709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 3511709 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 58
Study 29281797 — intervention group
Group type: EXPERIMENTAL
Intervention: Three 3.5-mm knotless screw-in anchors
Number of subjects: 36
Study 29281797 — intervention group
Group type: COMPARATOR
Intervention: Four-anchor hybrid construct (two 3.0-mm knotted push-in anchors and two 2.9-mm knotless push-in anchors)
Number of subjects: 36
Study 29281797 — intervention group
Group type: COMPARATOR
Intervention: Three 3.0-mm knotless push-in anchors
Number of subjects: 36
Study 28579744 — intervention group
Group type: EXPERIMENTAL
Intervention: TearLab Osmolarity System
Number of subjects: 20
Study 28579744 — intervention group
Group type: COMPARATOR
Intervention: i-Med i-Pen
Number of subjects: 20
Study 29144074 — intervention group
Group type: EXPERIMENTAL
Intervention: Early NASG application at clinic level
Number of subjects: 0
Study 29144074 — intervention group
Group type: COMPARATOR
Intervention: Standard management for OH at clinic level, NASG applied at RH (Control)
Number of subjects: 0
Study 23615499 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange (PLEX)
Number of subjects: 137
Study 23615499 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylprednisolone (IV MeP)
Number of subjects: 137
Study 23615499 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary composite outcome (death or ESRD)
Number of subjects: 137
Study 23615499 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause death
Number of subjects: 137
Study 23615499 — intervention group
Group type: EXPERIMENTAL
Intervention: ESRD
Number of subjects: 137
Study 21322282 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir (induction and maintenance treatment)
Number of subjects: 76
Study 21322282 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 76
Study 18400708 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ)
Number of subjects: 18
Study 18400708 — intervention group
Group type: EXPERIMENTAL
Intervention: Furanocoumarin-free grapefruit juice
Number of subjects: 18
Study 18400708 — intervention group
Group type: COMPARATOR
Intervention: Orange juice (control)
Number of subjects: 18
Study 16596926 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelson‐Moberg Expanded CONSORT Instrument (NMECI)
Number of subjects: 14
Study 16596926 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrater reliability of NMECI
Number of subjects: 14
Study 16596926 — intervention group
Group type: EXPERIMENTAL
Intervention: Kappa statistics for individual sub‐items
Number of subjects: 14
Study 12686276 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory processing training software for 8 weeks
Number of subjects: 0
Study 12686276 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal‐learning and learning‐impaired children who did not participate in any remedial programs)
Number of subjects: 0
Study 10880804 — intervention group
Group type: COMPARATOR
Intervention: Control EEG from 26 healthy subjects
Number of subjects: 51
Study 10880804 — intervention group
Group type: EXPERIMENTAL
Intervention: Interictal EEG from 25 patients
Number of subjects: 51
Study 10880804 — intervention group
Group type: EXPERIMENTAL
Intervention: Ictal EEG from 25 patients
Number of subjects: 51
Study 10880804 — intervention group
Group type: COMPARATOR
Intervention: Control EEG from 26 healthy subjects and patients
Number of subjects: 51
Study 10880804 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG correlation dimension
Number of subjects: 51
Study 9200528 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine doses ranged from 10 to 40 mg/day
Number of subjects: 18
Study 1555692 — intervention group
Group type: EXPERIMENTAL
Intervention: Long protocol (subcutaneous buserelin acetate 200 micrograms/d from day 1, hMG started after 14 days)
Number of subjects: 91
Study 1555692 — intervention group
Group type: COMPARATOR
Intervention: Short protocol (subcutaneous buserelin acetate 200 micrograms/d from day 2, hMG from day 3)
Number of subjects: 91
Study 3904102 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MPN) 375 mg administered in 3 equal doses IV just prior to chemotherapy and then IM 6 and 12 hours after treatment
Number of subjects: 60
Study 3904102 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (MCP) 1 mg/kg administered in 3 equal doses IV just prior to chemotherapy and then IM 6 and 12 hours after treatment
Number of subjects: 60
Study 30881606 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management plus physiotherapy
Number of subjects: 8
Study 30881606 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy only
Number of subjects: 8
Study 30107488 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 g full-fat Irish cheddar cheese (FFCC)
Number of subjects: 164
Study 30107488 — intervention group
Group type: COMPARATOR
Intervention: Butter (49 g), calcium caseinate powder (30 g), and Ca supplement (CaCO3) (500 mg) (BCC)
Number of subjects: 164
Study 30107488 — intervention group
Group type: COMPARATOR
Intervention: 120 g reduced-fat Irish cheddar cheese + butter (21 g) (RFC + B)
Number of subjects: 164
Study 30107488 — intervention group
Group type: COMPARATOR
Intervention: 120 g FFCC (as per A) after a 6-wk run-in period
Number of subjects: 164
Study 27496255 — intervention group
Group type: EXPERIMENTAL
Intervention: Employment-focused case management (CMRE)
Number of subjects: 320
Study 27496255 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 320
Study 27496255 — intervention group
Group type: EXPERIMENTAL
Intervention: CMRE
Number of subjects: 320
Study 27496255 — intervention group
Group type: COMPARATOR
Intervention: SC
Number of subjects: 320
Study 25481088 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone administration once per week for 8 weeks starting 2 weeks prior to surgery
Number of subjects: 0
Study 25481088 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo intramuscularly instead of testosterone
Number of subjects: 0
Study 22440853 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus casei Shirota) - 2 bottles of fermented milk containing ≥ 6.5 × 10(9) live LcS/bottle for 176 days
Number of subjects: 737
Study 22440853 — intervention group
Group type: COMPARATOR
Intervention: Placebo (similar drink with no bacteria)
Number of subjects: 737
Study 20392360 — intervention group
Group type: EXPERIMENTAL
Intervention: Home non-invasive ventilation (NIV)
Number of subjects: 47
Study 20392360 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP) 5 cm H(2)O
Number of subjects: 47
Study 18511650 — intervention group
Group type: EXPERIMENTAL
Intervention: Abetimus sodium 600 mg
Number of subjects: 24
Study 18511650 — intervention group
Group type: EXPERIMENTAL
Intervention: Abetimus sodium 1200 mg
Number of subjects: 24
Study 18511650 — intervention group
Group type: EXPERIMENTAL
Intervention: Abetimus sodium 2400 mg
Number of subjects: 24
Study 18511650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 18511650 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of abetimus sodium
Number of subjects: 24
Study 16425357 — intervention group
Group type: EXPERIMENTAL
Intervention: He Jie Tang (HJT)
Number of subjects: 85
Study 16425357 — intervention group
Group type: COMPARATOR
Intervention: Combined medication (Control group)
Number of subjects: 85
Study 12874182 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotrafiban 30 or 50 mg BID
Number of subjects: 9190
Study 12874182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9190
Study 12874182 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin >162 mg/d
Number of subjects: 9190
Study 10808042 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (6 mg SQ)
Number of subjects: 20
Study 10808042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8657986 — intervention group
Group type: COMPARATOR
Intervention: Flunitrazepam
Number of subjects: 80
Study 8657986 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian and hops tablets
Number of subjects: 80
Study 8657986 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian syrup
Number of subjects: 80
Study 8657986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 1515258 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene 20 mg
Number of subjects: 369
Study 1515258 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene 40 mg
Number of subjects: 369
Study 1515258 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene 100 mg
Number of subjects: 369
Study 1515258 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene (all doses)
Number of subjects: 369
Study 6394143 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolfenamic acid (200 mg)
Number of subjects: 49
Study 6394143 — intervention group
Group type: COMPARATOR
Intervention: Caffeine (100 mg)
Number of subjects: 49
Study 6394143 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (10 mg)
Number of subjects: 49
Study 6394143 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolfenamic acid + Caffeine (200 mg + 100 mg)
Number of subjects: 49
Study 6394143 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolfenamic acid + Metoclopramide (200 mg + 10 mg)
Number of subjects: 49
Study 6394143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 31032783 — intervention group
Group type: COMPARATOR
Intervention: Topical minoxidil 5% lotion applied twice daily
Number of subjects: 30
Study 31032783 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesotherapy injected once weekly
Number of subjects: 30
Study 29061185 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Navigator intervention (n=30), up to ten sessions over 6 months.
Number of subjects: 40
Study 29061185 — intervention group
Group type: COMPARATOR
Intervention: Standard care and written information about local community resources (Control group, n=10).
Number of subjects: 40
Study 29061185 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews with participants, staff, and stakeholders.
Number of subjects: 40
Study 29061185 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential primary and secondary outcomes for future trial.
Number of subjects: 40
Study 25421606 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive Memory Training (COMET)
Number of subjects: 65
Study 25421606 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 65
Study 24657006 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (module theme: people-themed)
Number of subjects: 176
Study 24657006 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (module theme: thoughts-themed)
Number of subjects: 176
Study 21851027 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA with 0.125% bupivacaine and fentanyl (2 mcg/ml) with adrenaline (2 mcg/ml) (ABF group)
Number of subjects: 164
Study 21851027 — intervention group
Group type: COMPARATOR
Intervention: PCEA with 0.125% bupivacaine and fentanyl (2 mcg/ml) without adrenaline (BF group)
Number of subjects: 164
Study 19138601 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (MXF) 400 mg/24 hours for 5 days
Number of subjects: 100
Study 19138601 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin and clavulanic acid (AMX-CLV) 500/125 mg/8 hours for 5 days
Number of subjects: 100
Study 17366288 — intervention group
Group type: EXPERIMENTAL
Intervention: ABLE patients
Number of subjects: 699
Study 17366288 — intervention group
Group type: COMPARATOR
Intervention: Non-ABLE patients
Number of subjects: 699